We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cellular Barcoding Used to Characterize Clones of Breast Tumor Cells

By LabMedica International staff writers
Posted on 12 Mar 2019
Cancer researchers used an advanced cellular barcoding technique to characterize cells in primary and disseminated tumors in mouse models of human triple-negative breast cancer.

Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR), and HER2/neu. More...
Lack of these receptors increases the difficulty of treating the disease, since most hormone therapies target one of the three receptors. Primary triple negative breast cancers are prone to dissemination but sub-clonal relationships between tumors and resulting metastases are poorly understood.

To help clarify this relationship, investigators at the Walter and Eliza Hall Institute of Medical Research (Melbourne, Australia) worked with mouse models carrying two treatment-naïve TNBC patient-derived xenografts (PDXs) in order to track the fate of thousands of barcoded clones in primary tumors, and their metastases.

The investigators sought to capture the majority of tumor biomass and tumor cells at distal sites, and examine their heterogeneity in an unbiased fashion. Distal sites included cells that had shed from the primary tumor and were found in the blood stream as circulating tumor cells (CTCs), or in other distal organs (e.g. lung, bone marrow, ovaries, and kidney) where they accumulated as disseminated tumor cells (DTCs).

To accomplish this task, the investigators utilized cellular barcoding, which allowed robust assessment of clonal diversity and numbers at high resolution and depth, including confident detection of clones as small as five to 10 cells amongst millions.

The investigators reported in the February 15, 2019, online edition of the journal Nature Communications that tumor resection had a major impact on reducing clonal diversity in secondary sites, indicating that most disseminated tumor cells lacked the capacity to "seed", and therefore originated from "shedders" that did not persist. The few clones that continued to grow after resection ("seeders") did not correlate in frequency with their parental clones in primary tumors. Cisplatin treatment of one BRCA1-mutated PDX model had a surprisingly minor impact on clonal diversity in the relapsed tumor yet purged 50% of distal clones. Therefore, clonal features of shedding, seeding, and drug resistance are important factors to consider for the design of therapeutic strategies.

"The barcoding technique," said first author Dr. Delphine Merino, head of the tumor progression and heterogeneity laboratory, at the Olivia Newton-John Cancer Research Institute (Melbourne, Australia), "enabled us to identify the clones that were able to get into the bloodstream and make their way into other organs where they would "seed" new tumor growth. Our study revealed that only a select few clones were actually responsible for the metastasis."

Related Links:
Walter and Eliza Hall Institute of Medical Research
Olivia Newton-John Cancer Research Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.